SARS-COV-2 MPRO Inhibitors With Antiviral Activity In A Transgenic Mouse Model

March 26, 2021


A recent breakthrough paper in Science Magazine  discusses possible new therapeutics for SARS-CoV-2 using our humanized ACE2 models for COVID research. Please contact us to find out more about the hACE2 model at sales@gempharmatech.us.


Read the full article at: science.sciencemag.org


Next : GemPharmatech Co., Ltd. Opens New Operations In United States To House More Than 6000 Research Mouse Models Previous：GemPharmatech and UC Davis Sign Agreement to Distribute Mouse Models in the US to Better Serve US Academic and Pre-Clinical R&D Communities